Immunosuppression in solid organ transplantation is currently experiencing a worldwide revival since new drugs are now available and others are under development. In order to contribute to the design of future strategies, a critical approach of surrogate endpoints is given and long-term side effects are analysed, together with the impact of non-compliance, quality-of-life and economical parameters. In this book, international specialists have set up the scientific rationale and provided new bases for further immunosuppressive strategies.
Immunosuppression in solid organ transplantation is currently experiencing a worldwide revival since new drugs are now available and others are under development. In order to contribute to the design of future strategies, a critical approach of surrogate endpoints is given and long-term side effects are analysed, together with the impact of non-compliance, quality-of-life and economical parameters. In this book, international specialists have set up the scientific rationale and provided new bases for further immunosuppressive strategies.
Die Herstellerinformationen sind derzeit nicht verfügbar.
Inhaltsangabe
Preface. Part 1: Setting the stages in clinical trials. 1. Current results as reference for future improvements in immunosuppression; G. Opelz, et al. 2. Rationale of clinical trials from the physician; C. Legendre. 3. Minimal standards for reporting clinical trial results in transplantation; B.L. Kasiske, H. Chakkera. 4. Methodological approach of clinical trials for renal transplantation; P. Landais, J.P. Jais. Part 2: Is acute rejection an appropriate surrogate marker? 5. Surrogate end-points for clinical trials in renal transplantation; B.L. Kasiske. 6. Is acute rejection an appropriate surrogate marker for clinical trials in liver transplantation? O. Farges. 7. The success of clinical immunosuppressive trials in heart transplantation: the early detection of acute rejection; M. Antoine. Part 3: Towards long-term end-points. 8. Factors influencing long-term allograft survival; C. Van Buren. Part 4: Can we minimize the long-term side-effects? 9. Patients' appraisal of side-effects in quality of life assessments of immunosuppressive regimens; P. Moons, et al. 10. Cardiovascular complications after renal transplantation; V. Schwenger, et al. 11. Strategies to minimize nephrotoxicity associated with calcineurin inhibitors; J. Alsina. 12. Diabetogenic effect of immunosuppressive drugs; X. Martin. 13. Can we minimize long-term side effects of immunosuppressive drugs on lipid metabolism? Z.A. Massy. 14. Can we minimize the long-term side-effects of immunosuppressive drugs in pediatric patients? B. Tönshoff, et al. Part 5: Strategies. 15. Induction therapy; D. Abramowicz, K.M. Wissing. 16. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens; J. Dantal, et al. 17. Immunosuppression in composite tissue transplantation; J.-M. Dubernard, et al. 18. The search for immunosuppressive synergy; C. Van Buren. 19. Economic analysis of immunosuppression in transplantation: a review of recent studies in liver and kidney transplantation; J. Hutton. Part 6: Clinical trials for at-risk situations. 20. Questions raised by the exclusion of `at risk' conditions from current trials in organ transplantation; J.P. Revillard, et al. List of contributors.
Preface. Part 1: Setting the stages in clinical trials. 1. Current results as reference for future improvements in immunosuppression; G. Opelz, et al. 2. Rationale of clinical trials from the physician; C. Legendre. 3. Minimal standards for reporting clinical trial results in transplantation; B.L. Kasiske, H. Chakkera. 4. Methodological approach of clinical trials for renal transplantation; P. Landais, J.P. Jais. Part 2: Is acute rejection an appropriate surrogate marker? 5. Surrogate end-points for clinical trials in renal transplantation; B.L. Kasiske. 6. Is acute rejection an appropriate surrogate marker for clinical trials in liver transplantation? O. Farges. 7. The success of clinical immunosuppressive trials in heart transplantation: the early detection of acute rejection; M. Antoine. Part 3: Towards long-term end-points. 8. Factors influencing long-term allograft survival; C. Van Buren. Part 4: Can we minimize the long-term side-effects? 9. Patients' appraisal of side-effects in quality of life assessments of immunosuppressive regimens; P. Moons, et al. 10. Cardiovascular complications after renal transplantation; V. Schwenger, et al. 11. Strategies to minimize nephrotoxicity associated with calcineurin inhibitors; J. Alsina. 12. Diabetogenic effect of immunosuppressive drugs; X. Martin. 13. Can we minimize long-term side effects of immunosuppressive drugs on lipid metabolism? Z.A. Massy. 14. Can we minimize the long-term side-effects of immunosuppressive drugs in pediatric patients? B. Tönshoff, et al. Part 5: Strategies. 15. Induction therapy; D. Abramowicz, K.M. Wissing. 16. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens; J. Dantal, et al. 17. Immunosuppression in composite tissue transplantation; J.-M. Dubernard, et al. 18. The search for immunosuppressive synergy; C. Van Buren. 19. Economic analysis of immunosuppression in transplantation: a review of recent studies in liver and kidney transplantation; J. Hutton. Part 6: Clinical trials for at-risk situations. 20. Questions raised by the exclusion of `at risk' conditions from current trials in organ transplantation; J.P. Revillard, et al. List of contributors.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
